Somatostatin administration prior to ERCP is effective in reducing the risk of post-ERCP pancreatitis in high-risk patients

Author：

Publisher： Spandidos Publications

ISSN： 1792-0981

Source： Experimental and Therapeutic Medicine, Vol.8, Iss.2, 2014-01, pp. : 509-514

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Paclitaxel-containing High-dose Chemotherapy in High-risk Breast Cancer Patients

By Greinix Hildegard T. Linkesch Werner Seifert Manfred Kubista Ernst Czerwenka Klaus Elahi Fariborz Zielinski Christoph Hoecker Paul Steger Günther Schulenburg Axel Neumeister Geralt Rabitsch Werner Jakesz Raimund Kalhs Peter

Acta Oncologica, Vol. 39, Iss. 1, 2000-04 ,pp. : 47-52

Informa Healthcare

Access to resources Recommend Favorite

Intermediate- and high-risk melanoma

By Agarwala Sanjiv

Current Treatment Options in Oncology, Vol. 3, Iss. 3, 2002-06 ,pp. : 205-217

Springer Publishing Company

Access to resources Recommend Favorite

Treatment options for multiple myeloma patients with high-risk disease

By Ailawadhi Sikander Masood Aisha Sher Taimur Miller Kena Wood Margaret Lee Kelvin Chanan-Khan Asher

Medical Oncology, Vol. 27, Iss. 1, 2010-06 ,pp. : 53-61

Humana Press, Inc

Access to resources Recommend Favorite

Thermochemotherapy in patients with extremity high-risk soft tissue sarcomas (HR-STS)

By Schlemmer M. Wendtner C. M. Lindner L. Abdel-Rahman S. Hiddemann W. Issels R. D.

International Journal of Hyperthermia, Vol. 26, Iss. 2, 2010-12 ,pp. : 127-135

Informa Healthcare

Access to resources Recommend Favorite

The high-risk prostate cancer patient

By Hussain M.

Urologic Oncology: Seminars and Original Investigations, Vol. 21, Iss. 3, 2003-05 ,pp. : 211-211

Elsevier

Access to resources Recommend Favorite